 Whitney High
Concepts (386)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Skin Neoplasms | 16 | 2024 | 852 | 2.270 |
Why?
| | Melanoma | 13 | 2020 | 761 | 2.080 |
Why?
| | Skin Diseases | 10 | 2013 | 152 | 1.850 |
Why?
| | Dermatology | 5 | 2013 | 131 | 1.210 |
Why?
| | Skin Diseases, Vesiculobullous | 4 | 2011 | 17 | 1.150 |
Why?
| | Immunohistochemistry | 14 | 2020 | 1723 | 1.020 |
Why?
| | Nephrogenic Fibrosing Dermopathy | 6 | 2012 | 8 | 0.940 |
Why?
| | Nevus, Pigmented | 4 | 2020 | 35 | 0.880 |
Why?
| | Gadolinium DTPA | 6 | 2012 | 70 | 0.820 |
Why?
| | Bedbugs | 2 | 2017 | 2 | 0.810 |
Why?
| | Contrast Media | 9 | 2012 | 497 | 0.730 |
Why?
| | Malpractice | 3 | 2013 | 44 | 0.720 |
Why?
| | Skin | 11 | 2011 | 754 | 0.700 |
Why?
| | Lupus Erythematosus, Cutaneous | 3 | 2007 | 7 | 0.690 |
Why?
| | Gadolinium | 4 | 2010 | 84 | 0.690 |
Why?
| | Dermatitis, Allergic Contact | 3 | 2006 | 73 | 0.600 |
Why?
| | Psoriasis | 3 | 2013 | 115 | 0.540 |
Why?
| | Skin Ulcer | 1 | 2018 | 15 | 0.540 |
Why?
| | Kidney Failure, Chronic | 3 | 2009 | 599 | 0.530 |
Why?
| | Histiocytosis, Langerhans-Cell | 2 | 2008 | 36 | 0.530 |
Why?
| | Seminoma | 1 | 2018 | 20 | 0.530 |
Why?
| | Ectoparasitic Infestations | 1 | 2017 | 5 | 0.510 |
Why?
| | Dermatitis, Atopic | 3 | 2013 | 322 | 0.500 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 1 | 2018 | 76 | 0.490 |
Why?
| | Testicular Neoplasms | 1 | 2018 | 111 | 0.480 |
Why?
| | Erythema | 3 | 2009 | 28 | 0.470 |
Why?
| | Scrotum | 2 | 2018 | 25 | 0.470 |
Why?
| | Nail Diseases | 2 | 2006 | 9 | 0.450 |
Why?
| | Fibrosis | 6 | 2008 | 561 | 0.430 |
Why?
| | Neurothekeoma | 1 | 2014 | 4 | 0.410 |
Why?
| | Defensive Medicine | 1 | 2013 | 4 | 0.410 |
Why?
| | Telepathology | 1 | 2013 | 4 | 0.410 |
Why?
| | Licensure | 1 | 2013 | 16 | 0.400 |
Why?
| | Humans | 70 | 2024 | 145763 | 0.400 |
Why?
| | Medicare | 1 | 2020 | 904 | 0.400 |
Why?
| | Diagnostic Errors | 2 | 2012 | 178 | 0.390 |
Why?
| | Antibodies, Monoclonal | 3 | 2014 | 1505 | 0.380 |
Why?
| | Lupus Erythematosus, Discoid | 2 | 2015 | 5 | 0.350 |
Why?
| | Scabies | 1 | 2011 | 3 | 0.340 |
Why?
| | Elephantiasis | 1 | 2011 | 3 | 0.340 |
Why?
| | Genital Diseases, Male | 1 | 2011 | 16 | 0.340 |
Why?
| | Hidradenitis Suppurativa | 1 | 2011 | 11 | 0.340 |
Why?
| | Ganglion Cysts | 1 | 2011 | 10 | 0.340 |
Why?
| | Acromioclavicular Joint | 1 | 2011 | 12 | 0.340 |
Why?
| | Diagnosis, Differential | 10 | 2024 | 1512 | 0.330 |
Why?
| | Biopsy | 7 | 2021 | 1082 | 0.320 |
Why?
| | Male | 39 | 2024 | 73003 | 0.310 |
Why?
| | Piperazines | 2 | 2012 | 375 | 0.300 |
Why?
| | Biomarkers, Tumor | 5 | 2024 | 1329 | 0.300 |
Why?
| | Insect Bites and Stings | 1 | 2009 | 13 | 0.300 |
Why?
| | Cocaine | 2 | 2012 | 162 | 0.300 |
Why?
| | Spectrometry, Fluorescence | 1 | 2009 | 165 | 0.290 |
Why?
| | Keratoacanthoma | 1 | 2008 | 2 | 0.290 |
Why?
| | Keratolytic Agents | 1 | 2008 | 5 | 0.290 |
Why?
| | Isotretinoin | 1 | 2008 | 26 | 0.280 |
Why?
| | Pyrimidines | 2 | 2012 | 530 | 0.280 |
Why?
| | Antineoplastic Agents | 3 | 2010 | 2219 | 0.280 |
Why?
| | Hypersensitivity, Delayed | 1 | 2008 | 29 | 0.280 |
Why?
| | Pyroglyphidae | 1 | 2008 | 18 | 0.280 |
Why?
| | Syphilis | 2 | 2005 | 38 | 0.270 |
Why?
| | Pathology, Clinical | 1 | 2008 | 29 | 0.270 |
Why?
| | Sweet Syndrome | 1 | 2007 | 10 | 0.270 |
Why?
| | Adult | 28 | 2020 | 40872 | 0.260 |
Why?
| | Scleroderma, Systemic | 1 | 2008 | 123 | 0.260 |
Why?
| | Kidney Diseases | 2 | 2008 | 426 | 0.260 |
Why?
| | Female | 37 | 2020 | 79035 | 0.250 |
Why?
| | Skin Diseases, Infectious | 1 | 2007 | 13 | 0.250 |
Why?
| | Alopecia | 2 | 2013 | 37 | 0.250 |
Why?
| | Dermatomyositis | 2 | 2004 | 24 | 0.250 |
Why?
| | Body Piercing | 1 | 2006 | 3 | 0.250 |
Why?
| | Antibodies, Antinuclear | 2 | 2004 | 62 | 0.250 |
Why?
| | Histiocytoma | 1 | 2006 | 2 | 0.250 |
Why?
| | Hemangiopericytoma | 1 | 2006 | 5 | 0.250 |
Why?
| | Lymphoma, T-Cell, Cutaneous | 1 | 2007 | 45 | 0.240 |
Why?
| | Communicable Diseases, Emerging | 1 | 2007 | 39 | 0.240 |
Why?
| | Epithelioid Cells | 1 | 2006 | 9 | 0.240 |
Why?
| | Dermatitis, Seborrheic | 1 | 2006 | 5 | 0.240 |
Why?
| | Middle Aged | 25 | 2024 | 36302 | 0.240 |
Why?
| | Granuloma, Pyogenic | 1 | 2006 | 10 | 0.240 |
Why?
| | Neoplastic Syndromes, Hereditary | 1 | 2007 | 47 | 0.240 |
Why?
| | Exanthema | 1 | 2007 | 86 | 0.240 |
Why?
| | Titanium | 1 | 2006 | 74 | 0.240 |
Why?
| | Granuloma | 1 | 2006 | 97 | 0.240 |
Why?
| | Aged | 21 | 2021 | 26215 | 0.230 |
Why?
| | Hyperkeratosis, Epidermolytic | 1 | 2005 | 21 | 0.230 |
Why?
| | Neoplasm Regression, Spontaneous | 1 | 2005 | 3 | 0.230 |
Why?
| | Genital Diseases, Female | 1 | 2005 | 31 | 0.230 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2007 | 101 | 0.220 |
Why?
| | Scalp | 1 | 2005 | 38 | 0.220 |
Why?
| | Allergens | 1 | 2008 | 386 | 0.220 |
Why?
| | Tacrolimus | 1 | 2006 | 196 | 0.220 |
Why?
| | Ossification, Heterotopic | 1 | 2004 | 18 | 0.220 |
Why?
| | Ear, External | 1 | 2004 | 21 | 0.220 |
Why?
| | Ear Diseases | 1 | 2004 | 20 | 0.210 |
Why?
| | Quinazolines | 1 | 2006 | 266 | 0.210 |
Why?
| | Tuberculosis, Miliary | 1 | 2004 | 4 | 0.210 |
Why?
| | Tuberculosis, Cutaneous | 1 | 2004 | 2 | 0.210 |
Why?
| | Antigens, CD20 | 1 | 2024 | 34 | 0.210 |
Why?
| | CD56 Antigen | 1 | 2024 | 34 | 0.210 |
Why?
| | Telemedicine | 1 | 2013 | 966 | 0.210 |
Why?
| | Mycosis Fungoides | 1 | 2024 | 63 | 0.210 |
Why?
| | Agave | 1 | 2003 | 1 | 0.200 |
Why?
| | Fibroma | 1 | 2004 | 21 | 0.200 |
Why?
| | Biopsy, Needle | 5 | 2011 | 185 | 0.200 |
Why?
| | Carcinoma, Squamous Cell | 3 | 2010 | 641 | 0.200 |
Why?
| | Alendronate | 1 | 2003 | 14 | 0.200 |
Why?
| | Tumor Virus Infections | 1 | 2003 | 51 | 0.200 |
Why?
| | Women's Health | 1 | 2005 | 316 | 0.190 |
Why?
| | Facial Dermatoses | 1 | 2003 | 17 | 0.190 |
Why?
| | AIDS-Related Opportunistic Infections | 1 | 2004 | 130 | 0.190 |
Why?
| | Vasculitis | 1 | 2003 | 69 | 0.190 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2006 | 346 | 0.190 |
Why?
| | Neoplasm Invasiveness | 2 | 2020 | 508 | 0.190 |
Why?
| | Protein Kinase Inhibitors | 2 | 2012 | 981 | 0.190 |
Why?
| | Hyperpigmentation | 1 | 2003 | 27 | 0.190 |
Why?
| | Papillomaviridae | 1 | 2003 | 116 | 0.190 |
Why?
| | Lymphatic Metastasis | 2 | 2019 | 336 | 0.180 |
Why?
| | Cicatrix | 1 | 2003 | 69 | 0.180 |
Why?
| | Antirheumatic Agents | 1 | 2005 | 307 | 0.180 |
Why?
| | Cheilitis | 1 | 2021 | 3 | 0.170 |
Why?
| | Pregnancy Outcome | 1 | 2005 | 504 | 0.170 |
Why?
| | United States | 7 | 2020 | 16123 | 0.170 |
Why?
| | Prognosis | 5 | 2017 | 4329 | 0.170 |
Why?
| | Patch Tests | 3 | 2008 | 60 | 0.160 |
Why?
| | MART-1 Antigen | 1 | 2020 | 8 | 0.160 |
Why?
| | Genetic Testing | 2 | 2017 | 483 | 0.150 |
Why?
| | SOXE Transcription Factors | 1 | 2020 | 22 | 0.150 |
Why?
| | Cannabis | 1 | 2007 | 510 | 0.150 |
Why?
| | Benzamides | 2 | 2012 | 226 | 0.150 |
Why?
| | Pulmonary Fibrosis | 1 | 2003 | 395 | 0.150 |
Why?
| | Pregnancy Complications | 1 | 2005 | 603 | 0.150 |
Why?
| | Head and Neck Neoplasms | 2 | 2019 | 561 | 0.150 |
Why?
| | Societies, Medical | 1 | 2003 | 900 | 0.150 |
Why?
| | Papillomavirus Infections | 1 | 2003 | 344 | 0.150 |
Why?
| | Aged, 80 and over | 8 | 2015 | 8346 | 0.140 |
Why?
| | Methotrexate | 3 | 2012 | 233 | 0.140 |
Why?
| | HIV Infections | 2 | 2004 | 3195 | 0.140 |
Why?
| | Dermoscopy | 2 | 2017 | 11 | 0.130 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2019 | 288 | 0.130 |
Why?
| | Retrospective Studies | 9 | 2020 | 17325 | 0.130 |
Why?
| | Comparative Genomic Hybridization | 1 | 2017 | 28 | 0.130 |
Why?
| | Gene Regulatory Networks | 1 | 2020 | 318 | 0.130 |
Why?
| | Lip | 2 | 2021 | 23 | 0.130 |
Why?
| | STAT3 Transcription Factor | 1 | 2019 | 206 | 0.130 |
Why?
| | Pruritus | 2 | 2009 | 60 | 0.130 |
Why?
| | Bites and Stings | 1 | 2017 | 30 | 0.120 |
Why?
| | Severity of Illness Index | 4 | 2009 | 2933 | 0.120 |
Why?
| | Tumor Suppressor Proteins | 1 | 2019 | 322 | 0.120 |
Why?
| | Risk Assessment | 6 | 2011 | 3752 | 0.120 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2017 | 328 | 0.120 |
Why?
| | Dermatologic Agents | 2 | 2013 | 68 | 0.120 |
Why?
| | Lichenoid Eruptions | 1 | 2015 | 2 | 0.120 |
Why?
| | Sampling Studies | 2 | 2007 | 98 | 0.120 |
Why?
| | Mutation | 1 | 2007 | 4090 | 0.110 |
Why?
| | Follow-Up Studies | 5 | 2011 | 5428 | 0.110 |
Why?
| | Renal Dialysis | 2 | 2009 | 466 | 0.110 |
Why?
| | Magnetic Resonance Imaging | 4 | 2011 | 3915 | 0.100 |
Why?
| | Child | 6 | 2014 | 22739 | 0.100 |
Why?
| | Mass Spectrometry | 2 | 2008 | 731 | 0.100 |
Why?
| | Face | 1 | 2015 | 175 | 0.100 |
Why?
| | Child, Preschool | 4 | 2014 | 11868 | 0.100 |
Why?
| | Insurance, Liability | 1 | 2013 | 8 | 0.100 |
Why?
| | Mohs Surgery | 2 | 2004 | 29 | 0.100 |
Why?
| | Liability, Legal | 1 | 2013 | 42 | 0.100 |
Why?
| | Animals | 8 | 2019 | 38097 | 0.100 |
Why?
| | Gene Expression Profiling | 1 | 2020 | 1777 | 0.100 |
Why?
| | Photography | 1 | 2013 | 119 | 0.100 |
Why?
| | Internship and Residency | 1 | 2003 | 1269 | 0.090 |
Why?
| | Antinematodal Agents | 1 | 2012 | 7 | 0.090 |
Why?
| | Imatinib Mesylate | 2 | 2012 | 77 | 0.090 |
Why?
| | Levamisole | 1 | 2012 | 22 | 0.090 |
Why?
| | Drug Contamination | 1 | 2012 | 54 | 0.090 |
Why?
| | Granulomatosis with Polyangiitis | 1 | 2012 | 47 | 0.090 |
Why?
| | Immunosuppressive Agents | 2 | 2009 | 838 | 0.090 |
Why?
| | Argyria | 1 | 2011 | 4 | 0.090 |
Why?
| | Fetal Diseases | 1 | 2013 | 194 | 0.090 |
Why?
| | Granuloma, Foreign-Body | 1 | 2011 | 8 | 0.090 |
Why?
| | Orphanages | 1 | 2011 | 2 | 0.090 |
Why?
| | Vietnam | 1 | 2011 | 27 | 0.090 |
Why?
| | Ethiopia | 1 | 2011 | 44 | 0.080 |
Why?
| | Foreign-Body Migration | 1 | 2011 | 33 | 0.080 |
Why?
| | Durapatite | 1 | 2011 | 37 | 0.080 |
Why?
| | Synovial Fluid | 1 | 2011 | 67 | 0.080 |
Why?
| | Adoption | 1 | 2011 | 25 | 0.080 |
Why?
| | Rupture | 1 | 2011 | 91 | 0.080 |
Why?
| | Cocaine-Related Disorders | 1 | 2012 | 133 | 0.080 |
Why?
| | Sensitivity and Specificity | 3 | 2020 | 2000 | 0.080 |
Why?
| | Mucins | 1 | 2011 | 75 | 0.080 |
Why?
| | Transcription Factors | 1 | 2019 | 1736 | 0.080 |
Why?
| | Pilot Projects | 2 | 2006 | 1897 | 0.080 |
Why?
| | Rotator Cuff Injuries | 1 | 2011 | 77 | 0.080 |
Why?
| | China | 1 | 2011 | 273 | 0.080 |
Why?
| | Aminolevulinic Acid | 1 | 2010 | 4 | 0.080 |
Why?
| | Injections, Intralesional | 1 | 2010 | 35 | 0.080 |
Why?
| | Health Care Costs | 1 | 2013 | 425 | 0.080 |
Why?
| | Eccrine Glands | 1 | 2009 | 2 | 0.080 |
Why?
| | Synchrotrons | 1 | 2009 | 12 | 0.080 |
Why?
| | Cell Differentiation | 1 | 2018 | 2050 | 0.080 |
Why?
| | Practice Guidelines as Topic | 2 | 2008 | 1582 | 0.080 |
Why?
| | Guatemala | 1 | 2011 | 343 | 0.080 |
Why?
| | Iron-Dextran Complex | 1 | 2009 | 7 | 0.080 |
Why?
| | Photopheresis | 1 | 2009 | 9 | 0.080 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2010 | 95 | 0.080 |
Why?
| | Treatment Outcome | 4 | 2012 | 11793 | 0.080 |
Why?
| | Ultraviolet Therapy | 1 | 2009 | 17 | 0.080 |
Why?
| | Plasmapheresis | 1 | 2009 | 24 | 0.080 |
Why?
| | Observation | 1 | 2009 | 54 | 0.080 |
Why?
| | Arthropod Vectors | 1 | 2009 | 7 | 0.080 |
Why?
| | Bedding and Linens | 1 | 2009 | 11 | 0.070 |
Why?
| | Adolescent | 5 | 2014 | 22573 | 0.070 |
Why?
| | Naphthoquinones | 1 | 2009 | 20 | 0.070 |
Why?
| | Algorithms | 1 | 2017 | 1850 | 0.070 |
Why?
| | Hyaluronic Acid | 1 | 2011 | 226 | 0.070 |
Why?
| | Fluorouracil | 1 | 2010 | 231 | 0.070 |
Why?
| | Vitiligo | 1 | 2009 | 42 | 0.070 |
Why?
| | Rituximab | 1 | 2010 | 210 | 0.070 |
Why?
| | Interferon-alpha | 1 | 2010 | 193 | 0.070 |
Why?
| | Interleukin-2 | 1 | 2010 | 440 | 0.070 |
Why?
| | Lymphoma, B-Cell | 1 | 2010 | 141 | 0.070 |
Why?
| | Erythropoietin | 1 | 2009 | 100 | 0.070 |
Why?
| | Histiocytes | 1 | 2008 | 7 | 0.070 |
Why?
| | Bleomycin | 1 | 2010 | 255 | 0.070 |
Why?
| | Histiocytosis | 1 | 2008 | 9 | 0.070 |
Why?
| | Langerhans Cells | 1 | 2008 | 12 | 0.070 |
Why?
| | Diabetes Insipidus | 1 | 2008 | 6 | 0.070 |
Why?
| | Failure to Thrive | 1 | 2008 | 28 | 0.070 |
Why?
| | Carcinoma, Skin Appendage | 1 | 2007 | 2 | 0.070 |
Why?
| | Microtubule-Associated Proteins | 1 | 2009 | 194 | 0.070 |
Why?
| | Prednisone | 2 | 2012 | 226 | 0.070 |
Why?
| | Antigen-Presenting Cells | 1 | 2008 | 159 | 0.070 |
Why?
| | Imidazoles | 1 | 2009 | 247 | 0.070 |
Why?
| | Risk Management | 1 | 2008 | 82 | 0.070 |
Why?
| | T-Lymphocytes, Helper-Inducer | 1 | 2008 | 132 | 0.060 |
Why?
| | Medical Records | 1 | 2008 | 192 | 0.060 |
Why?
| | Bone Diseases | 1 | 2008 | 61 | 0.060 |
Why?
| | Neoplasm Metastasis | 1 | 2010 | 688 | 0.060 |
Why?
| | Keratinocytes | 1 | 2008 | 249 | 0.060 |
Why?
| | Gnathostoma | 1 | 2007 | 1 | 0.060 |
Why?
| | Pythium | 1 | 2007 | 1 | 0.060 |
Why?
| | Spirurida Infections | 1 | 2007 | 1 | 0.060 |
Why?
| | Amoeba | 1 | 2007 | 5 | 0.060 |
Why?
| | Amebiasis | 1 | 2007 | 5 | 0.060 |
Why?
| | Receptor, Melanocortin, Type 1 | 1 | 2007 | 7 | 0.060 |
Why?
| | Penicillium | 1 | 2007 | 8 | 0.060 |
Why?
| | Genes, p16 | 1 | 2007 | 13 | 0.060 |
Why?
| | Electron Probe Microanalysis | 1 | 2006 | 3 | 0.060 |
Why?
| | Microphthalmia-Associated Transcription Factor | 1 | 2007 | 14 | 0.060 |
Why?
| | Epidermis | 1 | 2007 | 156 | 0.060 |
Why?
| | Case-Control Studies | 2 | 2020 | 3634 | 0.060 |
Why?
| | Skull | 1 | 2008 | 163 | 0.060 |
Why?
| | Paraffin Embedding | 1 | 2006 | 33 | 0.060 |
Why?
| | Factor XIIIa | 1 | 2006 | 6 | 0.060 |
Why?
| | Subcutaneous Tissue | 1 | 2006 | 26 | 0.060 |
Why?
| | Dermis | 1 | 2006 | 31 | 0.060 |
Why?
| | Hypopigmentation | 1 | 2006 | 3 | 0.060 |
Why?
| | Dosage Forms | 1 | 2006 | 11 | 0.060 |
Why?
| | Combined Modality Therapy | 1 | 2009 | 1270 | 0.060 |
Why?
| | Microscopy, Electron, Scanning | 1 | 2006 | 196 | 0.060 |
Why?
| | Neoplasms, Unknown Primary | 1 | 2006 | 20 | 0.060 |
Why?
| | Pregnancy | 3 | 2013 | 7215 | 0.060 |
Why?
| | Lysosomes | 1 | 2006 | 131 | 0.060 |
Why?
| | Organ Specificity | 1 | 2006 | 309 | 0.060 |
Why?
| | Tissue Distribution | 1 | 2006 | 335 | 0.060 |
Why?
| | Diabetic Nephropathies | 1 | 2009 | 322 | 0.060 |
Why?
| | Single-Blind Method | 1 | 2006 | 318 | 0.060 |
Why?
| | Acidosis | 1 | 2006 | 105 | 0.060 |
Why?
| | Metals | 1 | 2006 | 136 | 0.060 |
Why?
| | PTEN Phosphohydrolase | 1 | 2007 | 165 | 0.060 |
Why?
| | Viscera | 1 | 2005 | 17 | 0.060 |
Why?
| | Radiography | 1 | 2008 | 853 | 0.060 |
Why?
| | Pregnancy, Multiple | 1 | 2005 | 19 | 0.060 |
Why?
| | Remission, Spontaneous | 1 | 2005 | 39 | 0.060 |
Why?
| | Signal Transduction | 1 | 2019 | 5223 | 0.060 |
Why?
| | Mitosis | 1 | 2006 | 193 | 0.060 |
Why?
| | Rare Diseases | 1 | 2005 | 116 | 0.050 |
Why?
| | Treponema pallidum | 1 | 2004 | 10 | 0.050 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2007 | 224 | 0.050 |
Why?
| | Pregnancy Trimester, Third | 1 | 2005 | 119 | 0.050 |
Why?
| | Urticaria | 1 | 2005 | 38 | 0.050 |
Why?
| | Foot | 1 | 2005 | 103 | 0.050 |
Why?
| | Infliximab | 1 | 2005 | 111 | 0.050 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2007 | 337 | 0.050 |
Why?
| | Glucocorticoids | 2 | 2012 | 532 | 0.050 |
Why?
| | Renal Insufficiency | 1 | 2006 | 172 | 0.050 |
Why?
| | Sclerosis | 1 | 2004 | 11 | 0.050 |
Why?
| | Knee Joint | 1 | 2008 | 429 | 0.050 |
Why?
| | Hand | 1 | 2005 | 157 | 0.050 |
Why?
| | Twins | 1 | 2005 | 152 | 0.050 |
Why?
| | Iron | 1 | 2006 | 359 | 0.050 |
Why?
| | Infusions, Intravenous | 1 | 2005 | 428 | 0.050 |
Why?
| | Kidney Transplantation | 1 | 2010 | 712 | 0.050 |
Why?
| | Staining and Labeling | 1 | 2004 | 153 | 0.050 |
Why?
| | Nails | 1 | 2003 | 14 | 0.050 |
Why?
| | Infant, Newborn | 2 | 2007 | 6464 | 0.050 |
Why?
| | Infant | 2 | 2008 | 10090 | 0.050 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2020 | 1450 | 0.050 |
Why?
| | Chest Pain | 1 | 2004 | 99 | 0.050 |
Why?
| | Cell Nucleus | 1 | 2006 | 588 | 0.050 |
Why?
| | Quality of Health Care | 1 | 2008 | 693 | 0.050 |
Why?
| | Arm | 1 | 2003 | 110 | 0.050 |
Why?
| | Immunophenotyping | 1 | 2024 | 322 | 0.050 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2009 | 668 | 0.050 |
Why?
| | Cell Cycle Proteins | 1 | 2007 | 630 | 0.050 |
Why?
| | Fatal Outcome | 1 | 2003 | 305 | 0.050 |
Why?
| | Atrophy | 1 | 2003 | 199 | 0.050 |
Why?
| | Plant Leaves | 1 | 2003 | 131 | 0.050 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2006 | 534 | 0.050 |
Why?
| | Hip Dislocation | 1 | 2002 | 53 | 0.040 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2004 | 849 | 0.040 |
Why?
| | Adrenal Cortex Hormones | 1 | 2005 | 484 | 0.040 |
Why?
| | Cohort Studies | 3 | 2008 | 6032 | 0.040 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2004 | 238 | 0.040 |
Why?
| | Blotting, Western | 1 | 2004 | 1184 | 0.040 |
Why?
| | Coronary Disease | 1 | 2004 | 382 | 0.040 |
Why?
| | Plasma Cells | 1 | 2021 | 80 | 0.040 |
Why?
| | Hip Joint | 1 | 2002 | 173 | 0.040 |
Why?
| | Age Factors | 1 | 2008 | 3346 | 0.040 |
Why?
| | Young Adult | 2 | 2015 | 14251 | 0.040 |
Why?
| | Osteoporosis | 1 | 2003 | 239 | 0.040 |
Why?
| | Neoplasm Staging | 1 | 2004 | 1474 | 0.040 |
Why?
| | Arthroplasty, Replacement, Hip | 1 | 2002 | 183 | 0.040 |
Why?
| | Rats, Wistar | 2 | 2012 | 450 | 0.040 |
Why?
| | Respiratory Insufficiency | 1 | 2003 | 326 | 0.040 |
Why?
| | Reoperation | 1 | 2002 | 637 | 0.040 |
Why?
| | Kidney | 1 | 2007 | 1496 | 0.040 |
Why?
| | Risk Factors | 3 | 2009 | 10917 | 0.040 |
Why?
| | Genotype | 1 | 2003 | 1857 | 0.030 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2020 | 979 | 0.030 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2008 | 1969 | 0.030 |
Why?
| | Genetic Predisposition to Disease | 1 | 2007 | 2399 | 0.030 |
Why?
| | Mice, Nude | 1 | 2019 | 680 | 0.030 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2006 | 1191 | 0.030 |
Why?
| | Carcinogenesis | 1 | 2019 | 228 | 0.030 |
Why?
| | Arthritis, Rheumatoid | 1 | 2005 | 1180 | 0.030 |
Why?
| | T-Lymphocytes | 1 | 2024 | 1997 | 0.030 |
Why?
| | Phenotype | 1 | 2024 | 3170 | 0.030 |
Why?
| | Clinical Competence | 1 | 2003 | 1247 | 0.030 |
Why?
| | Early Detection of Cancer | 1 | 2020 | 486 | 0.030 |
Why?
| | Minoxidil | 1 | 2013 | 1 | 0.030 |
Why?
| | Clinical Decision-Making | 1 | 2017 | 364 | 0.030 |
Why?
| | Retinoids | 1 | 2013 | 36 | 0.030 |
Why?
| | Acne Vulgaris | 1 | 2013 | 25 | 0.020 |
Why?
| | Hydroxychloroquine | 1 | 2013 | 65 | 0.020 |
Why?
| | Lung Neoplasms | 1 | 2006 | 2667 | 0.020 |
Why?
| | Inflammation | 1 | 2004 | 2883 | 0.020 |
Why?
| | Rats | 2 | 2012 | 5585 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2003 | 5922 | 0.020 |
Why?
| | Injections, Intradermal | 1 | 2011 | 12 | 0.020 |
Why?
| | Cosmetic Techniques | 1 | 2011 | 19 | 0.020 |
Why?
| | Emergency Service, Hospital | 1 | 2004 | 2383 | 0.020 |
Why?
| | Disease Progression | 1 | 2019 | 2865 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2019 | 3551 | 0.020 |
Why?
| | Microscopy, Electron | 1 | 2011 | 414 | 0.020 |
Why?
| | Transcriptome | 1 | 2017 | 1042 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2003 | 6085 | 0.020 |
Why?
| | Incidence | 2 | 2010 | 2933 | 0.020 |
Why?
| | Epoetin Alfa | 1 | 2009 | 9 | 0.020 |
Why?
| | Injections, Intravenous | 1 | 2009 | 197 | 0.020 |
Why?
| | Drug Therapy, Combination | 1 | 2012 | 1043 | 0.020 |
Why?
| | Inhibitor of Apoptosis Proteins | 1 | 2009 | 46 | 0.020 |
Why?
| | Drug Synergism | 1 | 2009 | 354 | 0.020 |
Why?
| | Keratin-15 | 1 | 2007 | 16 | 0.020 |
Why?
| | Remission Induction | 1 | 2008 | 306 | 0.020 |
Why?
| | Axilla | 1 | 2006 | 51 | 0.010 |
Why?
| | Recombinant Proteins | 1 | 2009 | 1368 | 0.010 |
Why?
| | Antigens, Neoplasm | 1 | 2007 | 271 | 0.010 |
Why?
| | Proportional Hazards Models | 1 | 2009 | 1330 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2009 | 2028 | 0.010 |
Why?
| | Silver Staining | 1 | 2004 | 16 | 0.010 |
Why?
| | Databases, Factual | 1 | 2010 | 1491 | 0.010 |
Why?
| | Echocardiography, Stress | 1 | 2004 | 29 | 0.010 |
Why?
| | Calcium | 1 | 2009 | 1191 | 0.010 |
Why?
| | Causality | 1 | 2004 | 127 | 0.010 |
Why?
| | Probability | 1 | 2002 | 308 | 0.010 |
Why?
| | Age Distribution | 1 | 2002 | 404 | 0.010 |
Why?
| | Sex Distribution | 1 | 2002 | 388 | 0.010 |
Why?
| | Gastrointestinal Diseases | 1 | 2004 | 222 | 0.010 |
Why?
| | Mice | 1 | 2019 | 18355 | 0.010 |
Why?
| | Chi-Square Distribution | 1 | 2002 | 528 | 0.010 |
Why?
| | Exercise Test | 1 | 2004 | 630 | 0.010 |
Why?
| | Acute Disease | 1 | 2004 | 1036 | 0.010 |
Why?
| | Survival Analysis | 1 | 2004 | 1378 | 0.010 |
Why?
| | Recurrence | 1 | 2004 | 1139 | 0.010 |
Why?
| | Joint Instability | 1 | 2002 | 183 | 0.010 |
Why?
| | Electroencephalography | 1 | 2004 | 563 | 0.010 |
Why?
| | Hospitalization | 1 | 2004 | 2460 | 0.010 |
Why?
|
|
High's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|